N

NeoPharm Co Ltd
KOSDAQ:092730

Watchlist Manager
NeoPharm Co Ltd
KOSDAQ:092730
Watchlist
Price: 18 000 KRW -1.91%
Market Cap: 288.5B KRW

NeoPharm Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeoPharm Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
N
NeoPharm Co Ltd
KOSDAQ:092730
Operating Income
â‚©26.5B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
16%
AmorePacific Corp
KRX:090430
Operating Income
â‚©335B
CAGR 3-Years
16%
CAGR 5-Years
6%
CAGR 10-Years
-7%
Amorepacific Group
KRX:002790
Operating Income
â‚©363B
CAGR 3-Years
19%
CAGR 5-Years
5%
CAGR 10-Years
-8%
Cosmax Inc
KRX:192820
Operating Income
â‚©195.4B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
20%
LG H&H Co Ltd
KRX:051900
Operating Income
â‚©346.7B
CAGR 3-Years
-29%
CAGR 5-Years
-22%
CAGR 10-Years
-5%
Kolmar Korea Co Ltd
KRX:161890
Operating Income
â‚©223.1B
CAGR 3-Years
38%
CAGR 5-Years
19%
CAGR 10-Years
15%
No Stocks Found

NeoPharm Co Ltd
Glance View

Market Cap
281.5B KRW
Industry
Consumer products

NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.

Intrinsic Value
18 315.6 KRW
Undervaluation 2%
Intrinsic Value
Price
N

See Also

What is NeoPharm Co Ltd's Operating Income?
Operating Income
26.5B KRW

Based on the financial report for Jun 30, 2025, NeoPharm Co Ltd's Operating Income amounts to 26.5B KRW.

What is NeoPharm Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
16%

Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for NeoPharm Co Ltd have been 8% over the past three years , 4% over the past five years , and 16% over the past ten years .

Back to Top